MANA 2023

MANA Bruker Lunch Seminar on October 25, 2023 with guest speaker Gary Patti

MANA Bruker Lunch Seminar: Mapping Metabolic Fluxes in Tissue by using Mass Spectrometry-Based Imaging with guest speaker Gary Patti
October 25, 12:00 - 12:55 pm (CDT)

Join Bruker at the 5th Annual MANA Conference at our lunch seminar happening October 25, 2023 12:00 – 12:55 pm at the University of Missouri. Discover how Gary Patti is paving the way in MSI-based metabolic flux analysis of brain cancer with the timsTOF fleX MALDI-2

Location: Memorial Union, University of Missouri

12:00 pm – 12:05 pm Introduction
Dr. Erica Forsberg, Vice President Metabolomics, Bruker Daltonics, San Jose, CA

12:05 pm – 12:45 pm Mapping Metabolic Fluxes in Tissue by using Mass Spectrometry-Based Imaging
Dr. Gary Patti, Professor of Chemistry and of Genetics and Medicine, Washington University, St. Louis, MO

12:45 pm – 12:55 pm Q&A Session


Most commonly, mass spectrometry imaging has been applied to assess the relative levels of metabolites throughout a tissue. There are two main complications to interpreting these data. First, due to matrix effects, metabolite signal intensities can change between tissue regions independent of metabolite concentration.
Second, metabolite pathway activities cannot be accurately inferred from metabolite levels alone.

To overcome these challenges, we used mass spectrometry imaging to evaluate tissues from animals that had been labeled by 13C-enriched tracers. Then, by modeling the number of 13C-labels incorporated into metabolites and the fraction of metabolite labeled, we aimed to map the distribution of metabolic fluxes throughout tissue.

One notable limitation of our approach is being able to successfully resolve all of a metabolite's isotopologues from background signals, which interfere with the ability to measure full labeling patterns. To that end, we took advantage of trapped ion mobility spectroscopy (TIMS) to separate isotopically labeled versions of the same metabolite from other analytes prior to mass spectrometry analysis. When applied to a model of brain cancer, we found that de novo fatty acid synthesis flux is increased 3-fold in tumors relative to surrounding tissue. We also found that fatty acid elongation flux is elevated 8-fold relative to surrounding healthy tissue, highlighting a potential therapeutic target.

Dr. Gary Patti, Professor of Chemistry and of Genetics and Medicine, Washington University, St. Louis, MO

Register here

Sign up and get instant access to our exclusive content.

Input value is invalid.

Contact Information

Please enter your first name
Please enter your last name
Please enter a valid e-mail address
Please enter your Company/Institution

Marketing Consent:

Following of our interaction with you, Bruker Daltonics and its affiliates within the Bruker group (“Bruker”) would like to be able to stay in contact with you and inform you about the latest technological achievements and upcoming events as well as the products and services offered by Bruker. If you are interested in hearing from us in the future, we will need your consent in accordance with applicable data protection laws to be allowed to engage in marketing activities using your contact information. To view the promises that we make to you regarding your personal information, please view Bruker`s privacy policy. For questions related to privacy, please send your inquiry to . If you prefer not to receive promotional e-mails from Bruker in the future, you can unsubscribe any time. 

Please accept the Terms and Conditions


As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regards to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.

*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling. 

**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.


Thank you for registering for MANA Bruker Lunch Seminar. 


For Research Use Only. Not for use in clinical diagnostic procedures.